Background. Posttransplant lymphoproliferative disorders (PTLD) still represent a major preoccupation after renal transplantation, even in the most recent years. Methods. We analyzed the incidence, risk, and prognostic factors of PTLD in a cohort of kidney recipients using the United States Renal Data System. Results. Among 25,127 Medicare patients transplanted between 1996 and 2000, 344 developed a PTLD defined as a non-Hodgkin lymphoma (1.4%). History of pretransplant malignancy (adjusted hazard ratio [AHR]ϭ3.54, CI 2.31-5.43), younger age (AHRϭ1.91, CI 1.18 -3.1), fewer HLA matches (AHRϭ1.32, CI 1.1-1.59) and treatment by ATG (AHRϭ1.55, CI 1.2-1.99) and OKT3 (AHRϭ1.37, CI 1-1.76), especially if given for rejection therapy were associated with an increased risk of PTLD. Mycophenolate and azathioprine were associated with a lower risk of PTLD (AHRϭ0.6, CI 0.47-0.78 and AHRϭ0.66, CI 0.46 -0.95, respectively). IL2-receptor inhibitors and sirolimus did not modify the risk of PTLD. Patients without induction therapy treated with tacrolimus were at greater risk of lymphoma than those treated with new formulations of cyclosporine and those treated with antimetabolites (mycophenolate and azathioprine) have a lower risk of PTLD than those without. Patients with PTLD had poor survival (64% vs. 80% at 5 years). Older age, pretransplant malignancy and OKT3 were risk factors for death whereas treatment with mycophenolate was associated with a better survival (AHRϭ0.49, CIϭ0.28 -0.82). Conclusions. Our study highlights the contribution of patient history and immunosuppression in the risk of PTLD in the era of modern immunosuppression.
L ong-term complications of renal transplantation have assumed growing importance as short-term patient and graft survival has improved. Posttransplant lymphoproliferative disorders (PTLD) are a relatively rare but well-known complication after organ transplantation. In renal transplantation, the incidence of PTLD varies according to the series from 0.4% up to 10% in pediatric recipients, which confers a risk of lymphoma approximately 20-fold greater than seen in the general population (1) (2) (3) . Moreover, patients with PTLD have higher rates of mortality (3) . Recognized risk factors for PTLD are Epstein-Barr virus (EBV) seronegativity and overimmunosuppression, because most of the lymphoid proliferations are triggered by EBV in the setting of recipient deficient T-cell cytotoxicity. Nevertheless, the exact role of each immunosuppressive medication remains controversial with induction therapy using monoclonal antibody OKT3 the most involved risk factor implicated in development of PTLD (4, 5) . Other series highlighted the involvement of cyclosporine (6) or tacrolimus as risk factors for PTLD (3, 7, 8) . Over the last ten years, immunosuppression management has changed: emergence of monoclonal antibodies targeting interleukin (IL)-2 receptors which are less depressive of the immune system, diminution of OKT3 utilization and modification of maintenance therapy by the use of new formulations of cyclosporine or replacement of cyclosporine with tacrolimus as well as azathioprine with MMF and development of calcineurin inhibitor minimizing protocols using sirolimus. Some questions are raised by these adjustments of immunosuppression: do the new induction agents such as IL2-receptor inhibitors modify the rate of PTLD? Are the more potent immunosuppressive drugs such as tacrolimus or mycophenolate associated with higher risk of PTLD? Does the new molecule sirolimus influence this risk?
On the other hand, the implication of virus such as cytomegalovirus (CMV) or hepatitis C virus (HCV) as cofactors of EBV infection have been suggested in some publications as possible agents increasing the risk for PTLD (9 -11) .
The goal of our study was to analyze a nationwide transplant population in the setting of new immunosuppressive protocols. In this study, we analyzed epidemiologic, viral (EBV, CMV, HCV, and HBV) and iatrogenic (immunosuppressive medications) risk factors for developing PTLD and prognostic factors for patients' survival in the group of recipients who had developed a lymphoid proliferation.
METHODS
Data were obtained from the United States Renal Data System (USRDS), using standard analysis files (SAFs) as of October 2001. The variables included in the USRDS SAFs, as well as data collection methods and validation studies and demographics of the population, are listed at the USRDS website (http://www.usrds.org). SAF.TXUNOS was used as the primary dataset, and merged with variables from SAF. TXFUUNOS for follow-up data, Institutional Claims Details for Medicare Claims data, Physicians Suppliers for outpatients' data, SAF.RXHIST60 for previous dialysis modality and SAF.PATIENTS for dates and causes of death as well as causes of renal disease, as previously reported (12) . Because our outcome was a Medicare defined event, patients were limited to those who were identified as having Medicare as primary payer and excluding patients with Medicare as secondary payer at the time of renal transplantation or outcome. Limitations of the Medicare claim data have been described previously (13) . No age ranges were excluded, thus pediatric patients were included so long as they were eligible for Medicare at the time of transplant and event.
Our main outcome was Medicare Claim with a diagnosis of PTLD occurring after transplantation, based on the International Classification of Diseases 9th Modification Diagnosis Codes (ICD-9): codes 200x, 202x and 204x. We assessed the first Medicare Claim for PTLD after renal transplantation for a given individual who received a kidney transplant occurring between 1st January 1996 and 31 July 2000.
Associations between patient factors and Medicare Claims for PTLD risk were examined by unadjusted analysis and after adjusting for recipient age, race, gender, cause of ESRD (assessed as diabetes nephropathy, glomerulonephritis, posthypertensive and vascular nephropathies, malignant causes of renal insufficiency, cystic kidney diseases and others), duration of dialysis before transplantation, history of pretransplant malignancy, donor type and age, CMV, HCV, HBV and HIV status, human leukocyte antigen (HLA) match level, acute rejection occurring during the first year and immunosuppressive medications. Induction or rejection therapy included OKT3, antithymocyte globulins (ATG) and IL2-receptor inhibitors (Zenapax and Simulect). Antithymocyte globulins stood for ALG, Atgam, anti-thymocyte globulin, NRATG, NRATS, Medimmune and thymoglobulin codes. Cyclosporine was divided into old formulations: cyclosporin, CSA, Sandimmune, CyA, CyS, SangCyA, and new formulations: Neoral and Gengraf. Maintenance medications were considered if patient was treated both at discharge and during follow-up. The precise type of pretransplant malignancy couldn't be assessed from the database except when the malignant disease was the cause of renal insufficiency.
Time to PTLD was defined as the time from renal transplant until the date of claim for PTLD, with patients censored at death, loss to follow-up, 3 years after the date of transplant, or end of the study (which was considered 31 December, 2000, the most recent date of Medicare Claims available). Patient survival time was defined as the time from renal transplant to date of death, with patients censored five years after date of transplant (as the last follow up for date of death is October 2001).
Statistical Analysis
All analyses were performed using SPSS 11.5 TM (SPSS Inc., Chicago, IL). Files were merged and converted to SPSS files using DBMS/Copy (Conceptual Software, Houston, TX). Univariate analyses were performed with chi-square testing for categorical variables and Student's two-sided t test for continuous variables. Variables with PϽ0.10 in univariate analysis for a relationship with development of PTLD were entered into multivariate analysis as covariates. KaplanMeier analyses were used to construct survival plots of time to PTLD after renal transplantation and patient survival times after PTLD diagnosis. Comparisons were done using logrank test. Cox regression was used to model factors associated with time to PTLD, controlling for covariates listed above. The results of the Cox regression are presented as adjusted hazard ratio (AHR), their 95% confidence intervals (CI) and P values. Further analyses were also performed to investigate the effect of different maintenance therapies on the risk of PTLD, only in patients without induction to avoid confounding factors. Tacrolimus was compared to new formulations of cyclosporine as well as antimetabolites (mycophenolate and azathioprine taken together) were compared to the lack of antimetabolites and mycophenolate to azathioprine. These comparisons were also adjusted for all the factors included in the main model.
RESULTS
There were 25,127 kidney recipients meeting study criteria transplanted from January 1996 to July 2000, 19496 from deceased donors (77.6%) and 5631 from living donors (22.4%). Patients' ages varied from 1 to 98 years (mean 46.3Ϯ14.5 years). There were 10052 women (40%) and 15075 men (60%), 66% were white, 938 (3.7%) were multiorgan recipients and 17% were sensitized recipients. In all, 633 patients had a pretransplant malignancy and 118 of them had a malignancy-related cause of renal insufficiency. The "malignancy-related causes" of renal insufficiency were hemopathies in 14 cases (one kidney lymphoma, four myelomas and nine light chain deposit diseases), renal or urinary tract cancers in 67 cases, amyloidosis in 22 cases and nephrotoxicity of chemotherapy or radiotherapy in 15 cases. The remaining 515 recipients with a history of pretransplant malignancy had another cause of renal insufficiency and the type of malignancy was not known. In total, 343 donors had a history of cancer (103 intracranial, 24 extracranial, and 216 unknown).
Posttransplant lymphoproliferative disorders were diagnosed in 344 patients (1.4%) who were reported as developing non Hodgkin lymphoma. Table 1 summarizes patients' characteristics compared to the patients without PTLD. Twenty three recipients (6.7%) had a history of pretransplant malignancy. Six donors had a cancer history. Thirty-eight patients (11%) developed CMV disease before PTLD diagnosis and seven (2%) were hospitalized for acute hepatitis or encephalopathy related to HCV. Time to diagnosis of PTLD varied from 1 to 36 months (mean 12Ϯ9 months, median 9.5 months). One hundred and ninety eight PTLD (58%) occurred during the first year after transplantation and 146 after (42%). Ninety-two patients died (26.7%).
Risk factors for PTLD
Risk factors for PTLD are shown in Figs. 1-3 and Tables  1 and 2 .
Patients below 20 years of age had a greater risk of PTLD than adults (Pϭ0.02 by log-rank test; AHRϭ1. 22 We could not show any significant association between CMV, HBV or HCV recipient or donor status before transplantation and PTLD development. Occurrence of HCV-related disease after transplantation was not associated with PTLD occurrence whereas CMV disease was near statistical significance (Pϭ0.054 by log-rank test, NS in adjusted analysis). Data on EBV were not exhaustively analyzed because of missing data, but recipient seronegativity before transplantation was otherwise an important risk factor for the development of PTLD (Pϭ0.005 by log-rank test).
Overall usage of OKT3 and ATG were associated with a greater risk of PTLD (Pϭ0.009 by log-rank test; AHRϭ1.37, CIϭ1.1-1.76, Pϭ0.01 for OKT3 and Pϭ0.0007 by log-rank test; AHRϭ1.55, CIϭ1.2-2 Pϭ0.001 for ATG, Figure 2 ). When analyzed separately, thymoglobulin was not associated with an increased risk of PTLD (Pϭ0.37) but the number of treated patients was small (nϭ684). When used as anti-rejection therapy, ATG and OKT3 were associated with an increased risk of PTLD (Pϭ0.008 for ATG and Pϭ0.0003 for OKT3 by log rank-test) whereas OKT3 used for induction therapy was not (Pϭ0.6 by log-rank test). IL2-receptor antibodies did not increase the risk of PTLD.
Cyclosporine and MMF were associated with a reduced risk for PTLD in unadjusted analysis (Pϭ0.003 for cyclosporine and Pϭ0.0009 for MMF by log-rank test, Figure 3) . In adjusted analysis, only MMF and azathioprine were associated with a lower risk of PTLD (AHRϭ0.6, CIϭ0.47-0.78, Pϭ0.0001 for MMF and AHRϭ0.66, CIϭ0.46-0.95, Pϭ0.02 for azathioprine). Patients treated with a quadruple immunosuppressive regimen were at greater risk of lymphoma comparing to patients treated with 2 or 3 drugs (Pϭ0.01 by log-rank test, AHRϭ1.33 CIϭ1.06 -1.67, Pϭ0.012).
When immunosuppressive drugs were compared head-to-head in patients without induction, we found an increased risk of PTLD in patients treated by tacrolimus vs. cyclosporine (all forms), even when tacrolimus was compared to the new formulations of cyclosporine (Pϭ0.02 by log-rank test; AHRϭ1.57, CIϭ1.12-2.19 for tacrolimus vs. cyclosporine, Pϭ0.01 by log rank test; AHRϭ1.55, CIϭ1.1-2.2, Pϭ0.03, for tacrolimus vs. new formulations of cyclosporine). Hypothesizing that early use of tacrolimus was associated with higher serum levels of tacrolimus and overimmunosuppression, we stratified tacrolimus treated patients according to two era (96 -98 vs. 98 -2000) but the dif- ference was not significant (Pϭ0.37 by log rank test). There was a lower risk of PTLD in patients treated by antimetabolites vs. patients without (Pϭ0.001 by log-rank test), confirmed in adjusted analysis (AHRϭ0.61, CIϭ0.46 -0.81, Pϭ0.001). When MMF was directly compared to azathioprine, the difference did not reach the level of significance in terms of risk for PTLD.
Prognostic factors for patients with PTLD
Prognostic factors for patients with PTLD are shown in Fig. 4 and Table 2 .
PTLD represented a major risk factor for death among transplant recipients. Overall survival of patients with PTLD was 64% at 5 years vs. 80% for the other recipients (PϽ0.0001 by log-rank test). Risk factors for death in patients with PTLD were older age (Pϭ0.0004 by log-rank test; AHRϭ1. 8 had a lower risk of death (Pϭ0.003 by log-rank test; AHRϭ0.5, CIϭ0.32-0.9, Pϭ0.02 for MMF and Pϭ0.02 by log-rank test; NS in adjusted analysis for steroids). There was a better survival among patients without induction therapy treated by antimetabolites vs. no antimetabolites (Pϭ0.02 by log-rank test, AHRϭ0.46, CIϭ0.24 -0.89, Pϭ0.02), and by MMF vs. azathioprine in unadjusted and adjusted analyses (Pϭ0.008 by log-rank test, AHRϭ0.24, CIϭ0.1-0.69, Pϭ0.01).
DISCUSSION
Considering the Medicare transplant patients from the United States Renal Data System from 1996 to 2001, we found a cumulative incidence of 1.4% of lymphoproliferative disorders in the 3 years following kidney transplantation. This incidence is greater than that published in other series (2, 3, 14 -16) probably because of inclusion of pediatric patients and utilization of Medicare claims.
When analyzing the risk factors for developing PTLD, we found that age Ͻ20 years, recipient history of pretransplant malignancy and malignant cause of ESRD, recipient EBV-seronegativity, level of HLA matches and occurrence of acute rejection in the first year posttransplantation were the main epidemiologic factors associated with an increased risk of PTLD. Pediatric patients are known to be at risk for lymphoma, as they are frequently EBV-seronegative (17) . Opelz showed similar results demonstrating an increased risk of PTLD in the youngest and oldest patients (3). Recipient EBVseronegativity is a well-known risk factor of PTLD as EBV is the main oncogenic virus implicated in lymphomagenesis, especially in immunocompromised patients (18) . Despite some publications underlined a possible role of other viral coinfections by cytomegalovirus or hepatitis C virus (9 -11), we did not show evident relationship between seropositivity for these virus or viral diseases and the development of PTLD although there was a trend toward a higher rate of lymphomas after CMV disease occurrence. Recipient history of pretransplant malignancy as a risk factor of subsequent development of PTLD has not been demonstrated yet as a risk factor in large series. Nevertheless, a recent study from the Israel Penn International Transplant Tumor Registry (19) described the evolution of patients who underwent transplantation after a history of Hodgkin or non-Hodgkin lymphomas. The recurrence incidence was 10% with an increasing risk of relapse if the disease-free interval before transplantation was less than 2 years with poor survival of these patients. In our series, the incidence of relapse in the group of preexisting hematological malignancy was 28% with a subsequent rate of relapse for myeloma and light chain deposition diseases. Conversely, the risk of PTLD did not seem important after amyloidosis as no patients among 28 developed PTLD in the three years posttransplantation, but the precise type (AA or AL) of amyloidosis wasn't identified in the database.
Fewer HLA matches and acute rejection were risk factors of PTLD probably because they were associated with a greater amount of immunosuppression. In our series, patients with greater degree of HLA mismatch have more episodes of rejection and were more often treated by OKT3 or ATG. Nevertheless, the higher risk persists after adjusting by rejection occurrence and immunosuppressive medications, suggesting that other factors could be involved such as reduced MHC-restricted antigen-specific antiviral activity or amplified latent viral reactivation in the face of increased alloreactivity.
Considering the role of immunosuppression therapy, we confirmed the deleterious effect of ATG or OKT3 according to previous reports (3, 4, 14, 15) . After splitting the analysis according to induction or rejection usage of these drugs, we found that antirejection treatment was more deleterious than induction therapy, especially for OKT3. This could be explained by utilization of a higher cumulative dose of these (21) . By contrast, we showed that the IL2-receptor inhibitors were not associated with an increased risk of PTLD in the first three years after transplantation. Using the SRTR database, Bustami (14) reported an increased risk of PTLD in patients treated with daclizumab or basiliximab. These discrepancies could be explained by a difference in the sources of database and statistical methodology. Time to event for PTLD is less precise in SRTR database than from USRDS Medicare claims data. The overall incidence of PTLD in Bustami's series is only 0.43%, suggesting a probable underreporting of the PTLD cases, whereas this bias has been reduced in our study by considering Medicare Claims. In the CTS study (3), utilization of IL2-receptor inhibitors was not associated with an increased risk of PTLD but the analysis involved the first year posttransplantation.
In the current series, patients without induction therapy treated by cyclosporine were at lower risk of developing PTLD, compared to tacrolimus treated patients. In the same manner, Opelz showed that deceased-donor kidney recipients had a twofold greater risk of developing lymphoma with tacrolimus than with cyclosporine, limited to the group of patients without induction therapy (3). Our results are in accordance with these findings and with other reports of pediatric series where tacrolimus was associated with an increased risk for PTLD (8, 22) . Some previous papers (23, 24) suggested a deleterious role of cyclosporine which was not confirmed in the present study, but these series didn't compare cyclosporine and tacrolimus treated patients. In renal transplant recipients the more complete and constant absorption of Neoral resulted in an improved pharmacokinetic leading to a better therapeutic efficacy. Shah (25) conducted a meta-analysis of studies comparing Neoral and Sandimmune. The incidence of rejection was significantly lower in de novo renal, liver and heart transplant recipients. By reviewing the USRDS data, Meier-Kriesche (26) showed that the risk of chronic graft failure was significantly lower in patients treated with Neoral than in those treated with Sandimmune. Whether new formulations of cyclosporine (Neoral and Gengraf) increase or not the risk of lymphoma was of great interest. We showed that new formulations were associated with a lower risk of PTLD compared to tacrolimus. This is significant since tacrolimus and Neoral are now the primary calcineurin-inhibitors used in standard immunosuppressive regimens.
One of our more relevant results was that treatment with antimetabolites-mycophenolate or azathioprine-was associated with a lower risk of PTLD. The finding that MMFbased immunosuppression could be associated with a decreased risk of PTLD was not anticipated because of the potent immunosuppressive effect of this drug. In a report from UNOS database, Cherick reported as well a reduced risk of PTLD associated with mycophenolate, as this was suggested a few years ago with MMF in association with acyclovir in a monocentric series (15, 27) . Other studies did not notice that MMF and azathioprine lowered the risk for PTLD (3, 14) but the limitations of the SRTR study could explain this difference and the analysis of the CTS database was not focused on azathioprine or MMF treated patients. As the choice of immunosuppressive medication is often tailored to individual patients based on risk, we could wonder if these drugs were withheld in some groups of patients that were at increased risk for PTLD (such as EBV negative recipients, old recipients or patients with pretransplant malignancy). In our cohort, MMF and azathioprine treated patients were younger and had the same amount of pretransplant malignancy compared to the remaining recipients. EBV pretransplant serology was known in only 13% of MMF and azathioprine treated patients, a sample too small to obtain valid conclusions. Another bias could be a lower number of acute rejections and subsequent need for monoclonal antirejection therapy in MMF treated patients but all these factors were included in our multivariate analysis and MMF remained associated with a 40% decreased risk of PTLD in adjusted analysis. A direct inhibition of B cell proliferation by MMF could be an explanation as this drug is more potent on B cell suppression than the other immunosuppressive drugs (28, 29) .
Sirolimus acts as an inhibitor of B lymphoblastoid cells in vitro (30, 31) and could potentially be of interest for preventing PTLD in transplant recipients. We did not find any differences in terms of PTLD occurrence in patients treated with sirolimus, possibly because the number of patients treated by this medication was too small. More follow-up is needed to observe an eventual impact of sirolimus on PTLD incidence.
In terms of prognostic factors for patients' survival, we found that PTLD occurrence was associated with a major risk of death among transplant patients as their survival fell from 80% to 65% at 5 years. This finding is in accordance with the literature where the poor prognosis of this pathology in this population was largely depicted (3, 32) . Of note, there was no death among pediatric patients, underlining the better prognosis of PTLD in children most likely because of the greater frequency of polymorphic proliferations which could regress after lowering immunosuppression. However, our pediatric recipients may not represent the whole pediatric transplant population as children are more often covered by Medicaid. Risk factors for death in patients with PTLD were age above 60 years, existence of pretransplant malignancy and treatment by OKT3. Patients treated by MMF were at lower risk for death. Few large studies analyzed the risk factors for survival in patients suffering of lymphoid proliferations. Opelz found a survival rate of 60% after 1 year and around 40% after 5 years in kidney recipients with PTLD (3). He could establish a relationship between PTLD localization and survival which the present study could not, as localization of lymphoma is not declared in USRDS. The role of OKT3 and previous malignancies in worsening the prognosis could be explained by a greater vulnerability of these patients who are more susceptible to develop life-threatening cytopenia and infectious complications. In the French Registry of PostTransplant Lymphoproliferative Disorders, more than a third of deaths were related to infections or treatment toxicity (personal data).
